Loading...
Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...
Na minha lista:
| Udgivet i: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/ https://ncbi.nlm.nih.gov/pubmed/33474802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|